24 results on '"Carlson, Jennifer"'
Search Results
2. Abstract 5451: Testing a combination of AKT inhibitor (AZD5363) with PARP inhibitor olaparib plus carboplatin in TNBC
3. Abstract 1622: In vivo study of dasatinib in combination with veliparib plus carboplatin in triple-negative breast cancer xenograft models
4. Abstract 3451: Testing signaling algorithm in platinum-resistant ovarian carcinomas: A simultaneous inhibition of RAS-RAF and cell-cycle pathways signals by trametinib with paclitaxel or ribociclib/abemaciclib
5. Abstract 644: Validation of PD-L1 staining by IHC in solid tumors: A journey from xenograft model to ex vivo culture of clinical samples
6. Abstract 3452: TAK228, a kinase inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer model
7. Abstract B093: Signaling algorithm based on RAS-RAF and cell-cycle pathways’ alterations in precision medicine: rational combination of drugs in ovarian carcinoma
8. Abstract B092: Molecular aberrations of the PI3K-AKT-mTORC1/C2 pathway in ovarian cancers: a strategy for targeted therapy
9. Abstract 2883: Do Wnt3A-mediated canonical Wnt/Beta-catenin signals regulate stem cell phenotypes in brain metastasis-specific TNBC
10. Abstract 1359: How does RAC1 GTP-ase signal Wnt-beta-catenin pathway-mediated integrin-directed metastasis-associated tumor cell phenotypes in TNBC
11. Abstract 1348: GDC-0032, a p110 beta sparing PI3K inhibitor is highly efficient onPIK3CA-mutated andHER2-amplified breast cancer model
12. Abstract 4591: Estrogen receptor-positive breast cancer: from genomic landscape to treatment approach
13. Abstract 4605: Metastasis-associated tumor cell phenotypes in TNBC is regulated by Wnt-beta-catenin pathway signals
14. Abstract 3506: Carfilzomib demonstrates antiproliferative and proapoptotic activities in preclinical triple-negative breast cancer models
15. Abstract 4417:In vitroefficacy of dasatinib alone or in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer cell lines
16. Abstract 3303: Identifying a functional correlation between cancer stem cells and 3D clonogenic growth: testing rational combinations of PI3K pathway inhibitors in subtype-specific BC
17. Abstract 2561: Contextual combination of PARP inhibitors with p110beta inhibitors: Functional logistics to tame PTEN null tumors
18. Abstract 1980: Identification of the transcription factor ZNF217 in ER+ subset of BC: A functional relationship with the PI3K-AKT-mTOR pathway
19. Abstract 1966: Role of Wnt-Beta-Catenin signals in the control of vascular mimicry in TNBC
20. Abstract 1940: Dual inhibition of mTORC1/C2 and HER2 results in maximal antitumor efficacy in preclinical model of HER2+ breast cancer resistant to trastuzumab therapy
21. Abstract A15: Dual inhibition of the PI3K-mTOR signaling in combination with HER2 inhibitor is necessary for maximal antitumor activity in HER2+ breast cancer cells
22. Abstract A16: DDR-mediated antitumor actions of PARP inhibitor: Can PI3K-mTOR pathway inhibitor be combined with PARP inhibitor in TNBT?
23. Abstract 3443: Wnt-beta-catenin-Rac1 signaling axis regulates metastasis-associated phenotypes in TNBC
24. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.